Vir Biotechnology, Inc. Selling, General and Administrative Expense
Vir Biotechnology, Inc. (VIR) reported Selling, General and Administrative Expense of $30.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- Vir Biotechnology, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $30.20M, a 35.51% increase year-over-year.
- Vir Biotechnology, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $23.34M, a 2.53% decline year-over-year.
- Vir Biotechnology, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $23.62M, a 11.55% decline year-over-year.
- Vir Biotechnology, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $22.23M, a 13.65% decline year-over-year.
- Vir Biotechnology, Inc. selling, general and administrative expense for fiscal 2025 was $92.07M, a 22.65% decline from fiscal 2024.
- Vir Biotechnology, Inc. selling, general and administrative expense for fiscal 2024 was $119.03M, a 31.76% decline from fiscal 2023.
- Vir Biotechnology, Inc. selling, general and administrative expense for fiscal 2023 was $174.44M, a 7.84% increase from fiscal 2022.
- Vir Biotechnology, Inc. selling, general and administrative expense for fiscal 2022 was $161.76M, a 0.60% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $30.20M 10-Q · filed 2026-08-05 | $53.53M 10-Q · filed 2026-08-05 | $77.15M derived: sum of 3 quarters · filed 2026-08-05 | $99.38M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $23.34M 10-Q · filed 2026-05-07 | $46.95M derived: sum of 2 quarters · filed 2026-05-07 | $69.19M derived: sum of 3 quarters · filed 2026-05-07 | $91.47M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $23.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $45.85M derived: sum of 2 quarters · filed 2026-02-23 | $68.13M derived: sum of 3 quarters · filed 2026-08-05 | $92.07M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $22.23M 10-Q · filed 2025-11-05 | $44.51M derived: sum of 2 quarters · filed 2026-08-05 | $68.46M 10-Q · filed 2025-11-05 | $95.16M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $22.28M 10-Q · filed 2026-08-05 | $46.23M 10-Q · filed 2026-08-05 | $72.93M derived: sum of 3 quarters · filed 2026-08-05 | $98.67M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $23.94M 10-Q · filed 2026-05-07 | $50.65M derived: sum of 2 quarters · filed 2026-05-07 | $76.39M derived: sum of 3 quarters · filed 2026-05-07 | $106.65M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $26.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $52.45M derived: sum of 2 quarters · filed 2026-02-23 | $82.71M derived: sum of 3 quarters · filed 2026-02-23 | $119.03M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | $25.74M 10-Q · filed 2025-11-05 | $56.01M derived: sum of 2 quarters · filed 2025-11-05 | $92.33M 10-Q · filed 2025-11-05 | $133.55M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | $30.27M 10-Q · filed 2025-08-06 | $66.59M 10-Q · filed 2025-08-06 | $107.80M derived: sum of 3 quarters · filed 2026-02-23 | $148.74M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | $36.32M 10-Q · filed 2025-05-08 | $36.27M 10-Q · filed 2024-05-03 | $77.54M derived: sum of 2 quarters · filed 2026-02-23 | $118.47M derived: sum of 3 quarters · filed 2026-02-23 | $163.98M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2023-12-31 | $41.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $82.15M derived: sum of 2 quarters · filed 2026-02-23 | $127.66M derived: sum of 3 quarters · filed 2026-02-23 | $174.44M 10-K · filed 2026-02-23 | $178.05M 10-K · filed 2024-02-26 | |||
| 2023-09-30 | $40.93M 10-Q · filed 2024-11-04 | $41.08M 10-Q · filed 2023-11-03 | $86.44M derived: sum of 2 quarters · filed 2024-11-04 | $133.22M 10-Q · filed 2024-11-04 | $134.96M 10-Q · filed 2023-11-03 | $171.97M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $45.51M 10-Q · filed 2024-08-01 | $47.10M 10-Q · filed 2023-08-04 | $92.29M 10-Q · filed 2024-08-01 | $93.88M 10-Q · filed 2023-08-04 | $131.03M derived: sum of 3 quarters · filed 2025-02-27 | $174.21M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $46.78M 10-Q · filed 2024-05-03 | $85.52M derived: sum of 2 quarters · filed 2025-02-27 | $128.69M derived: sum of 3 quarters · filed 2025-02-27 | $170.28M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $38.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $81.92M derived: sum of 2 quarters · filed 2025-02-27 | $123.51M derived: sum of 3 quarters · filed 2025-02-27 | $161.76M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $43.17M 10-Q · filed 2023-11-03 | $84.76M derived: sum of 2 quarters · filed 2023-11-03 | $123.02M 10-Q · filed 2023-11-03 | $178.80M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $41.59M 10-Q · filed 2023-08-04 | $79.84M 10-Q · filed 2023-08-04 | $135.62M derived: sum of 3 quarters · filed 2024-02-26 | $186.12M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $38.26M 10-Q · filed 2023-05-08 | $94.03M derived: sum of 2 quarters · filed 2024-02-26 | $144.53M derived: sum of 3 quarters · filed 2024-02-26 | $173.31M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $55.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $106.27M derived: sum of 2 quarters · filed 2024-02-26 | $135.05M derived: sum of 3 quarters · filed 2024-02-26 | $160.79M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $50.50M 10-Q · filed 2022-11-03 | $79.28M derived: sum of 2 quarters · filed 2022-11-03 | $105.02M 10-Q · filed 2022-11-03 | $128.06M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $28.78M 10-Q · filed 2022-08-09 | $54.52M 10-Q · filed 2022-08-09 | $77.56M derived: sum of 3 quarters · filed 2023-02-28 | $96.42M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $25.74M 10-Q · filed 2022-05-05 | $48.78M derived: sum of 2 quarters · filed 2023-02-28 | $67.64M derived: sum of 3 quarters · filed 2023-02-28 | $84.03M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $23.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $41.90M derived: sum of 2 quarters · filed 2023-02-28 | $58.29M derived: sum of 3 quarters · filed 2023-02-28 | $70.94M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $18.86M 10-Q · filed 2021-11-04 | $35.24M derived: sum of 2 quarters · filed 2021-11-04 | $47.89M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $16.39M 10-Q · filed 2021-08-05 | $29.04M 10-Q · filed 2021-08-05 | ||||||
| 2019-12-31 | $37.60M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |